Novocure
NVCR
14.66
-0.31
-2.07%
Novocure
US · NVCR
#2889 by market cap
Listed 2015
14.66
-0.31
-2.07%
Live - 5344 symbols - heartbeat 565s ago
· 2026-10-08 08:04
Pre-market
14.00
-4.50%
After-hours
14.66
0.00%
Overnight
14.65
-0.07%
- Market cap
- 1.71B
- P/E (TTM)i
- -11.28
- P/Bi
- 5.05
- EPSi
- -1.22
- Div yieldi
- 0.00%
- 52W posi
- 42%
Reader sentiment
Are you bullish or bearish on NVCR?
Anonymous reader poll. Unscientific, not investment advice.
About Novocure
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, the United Kingdom.
- Founded
- 2000
- CEO
- Mr. Francis Leonard
- Employees
- 1,605
- Headquarters
- St. Helier, Jersey, United Kingdom of Great Britain and Northern Ireland (the)
- Fiscal year end
- 12-31
- Website
- novocure.com
Company profile
- Exchange
- US
- Symbol
- NVCR
- Market-cap rank
- #2889
- Listing date
- 2015-10-02
- Market cap
- 1.71B
- Float cap
- 1.41B
- Shares out
- 116.45M
- Float shares
- 96.42M
Sectors & themes
Medical Devices
Fractional Shares JP
Quote time 2026-10-08 08:04:50 · For reference only, not investment advice and not tailored to your situation.